Van't Hooft F M, Van Tol A
Biochem J. 1985 Mar 15;226(3):715-21. doi: 10.1042/bj2260715.
O-(4-Diazo-3-[125I]iodobenzoyl)sucrose ([125I]DIBS), a novel labelling compound specifically designed to study the catabolic sites of serum proteins [De Jong, Bouma, & Gruber (1981) Biochem. J. 198, 45-51], was applied to study the tissue sites of degradation of serum lipoproteins. [125I]DIBS-labelled apolipoproteins (apo) E and A-I, added in tracer amounts to rat serum, associate with high-density lipoproteins (HDL) just like conventionally iodinated apo E and A-I. No difference is observed between the serum decays of chromatographically isolated [125I]DIBS-labelled and conventionally iodinated HDL labelled specifically in either apo E or apo A-I. When these specifically labelled HDLs are injected into fasted rats, a substantial [125I]DIBS-dependent 125I accumulation occurs in the kidneys and in the liver. No [125I]DIBS-dependent accumulation is observed in the kidneys after injection of labelled asialofetuin or human low-density lipoprotein. It is concluded that the kidneys and the liver are important sites of catabolism of rat HDL apo E and A-I.
O-(4-重氮-3-[125I]碘苯甲酰基)蔗糖([125I]DIBS)是一种专门设计用于研究血清蛋白分解代谢部位的新型标记化合物[德容、布马和格鲁伯(1981年)《生物化学杂志》198卷,45 - 51页],被用于研究血清脂蛋白的降解组织部位。以示踪量添加到大鼠血清中的[125I]DIBS标记的载脂蛋白(apo)E和A-I,与高密度脂蛋白(HDL)结合的方式与传统碘化的apo E和A-I相同。在色谱分离的[125I]DIBS标记的和传统碘化的、分别在apo E或apo A-I中特异性标记的HDL的血清衰变之间未观察到差异。当将这些特异性标记的HDL注射到禁食的大鼠体内时,在肾脏和肝脏中会出现大量依赖于[125I]DIBS的125I积累。注射标记的去唾液酸胎球蛋白或人低密度脂蛋白后,在肾脏中未观察到依赖于[125I]DIBS的积累。结论是,肾脏和肝脏是大鼠HDL apo E和A-I分解代谢的重要部位。